BREAKING NEWS

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive
U.S. Distributor of PreTRM® Test. LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth

BREAKING NEWS

Clinical Innovation

Landmark PAPR Published Online in American Journal of Obstetrics & Gynecology View Press Release

BREAKING NEWS

Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test  Read More

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

News

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® Test

SALT LAKE CITY, January 10, 2017– LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth. Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test. PreTRM is the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. Read More >

Sera Prognostics to Present at 35th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, January 3, 2017 -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference. Dr. Critchfield’s presentation will take place at 7:30 AM PT on Tuesday, January 10th, 2017 in the Elizabethan Room at the Westin St. Francis Hotel in San Francisco, CA. Read More >

Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test

December 19, 2016 – Two recent publications show significant clinical utility of assessing preterm birth risk early in pregnancy with novel biomarker tests such as PreTRM®. These reports describe treatment paradigms that use existing interventions with significant potential to improve the health of premature babies, including reduction in mortality rates, as well as a corresponding reduction of direct medical costs to the health care system. Read More >

Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.